Study ID
(author,
year) |
N |
Design |
Setting |
Participants |
Participants Intervention
(experimental
group) |
Intervention
(control group)
Study |
Follow up |
Weibull et al.
(1993) |
58 |
Randomized
controlled
clinical trial |
Hospital,
Sweden |
58 patients without diabetes with severe
hypertension and
significant stenosis |
Percutanesous
Transluminal Renal
Angioplasty (PTRA) |
Operation |
24 mo |
Webster etal.
SNRASCG-trial
1998 |
135 |
Randomized
controlled
clinical trial |
Scottish Hospitals
Endowments Research Trust. |
135 eligible patients with hypertension and renovascular disease were identified |
Percutanesous
transluminal renal
angioplasty (PTRA |
Anti-hypertensive drug
therapy |
3–54 months |
Plouin et al
EMMA
(1998) |
49 |
Randomized
controlled
clinical trial |
Hospital Broussais, and INSERM U-36 (P.-F.P.), Paris, France. |
Patients were randomly assigned antihypertensive drug treatment (control group,
n.(26) or angioplasty n. (23) |
Percutanesous
transluminal renal
angioplasty (PTRA) with or without stent |
Anti-hypertensive drug
therapy |
6 month |
van deVen
et al.
(1999) |
85 |
Randomized
controlled
clinical trial |
Utrecht
University
hospital,
Netherlands |
85 patients with
Ostial atherosclerotic
renal artery stenosis |
Percutaneous
Transluminal
Angioplasty (PTA) |
Angioplasty with stent placement (PTAS) |
6 mo |
Jaarsveld
et al.
DRASTIC
(2000) |
106 |
Randomized
controlled
clinical trial |
Multicentre, US |
106 patients with
hypertension who
had atherosclerotic
renal-artery stenosis |
Percutaneous
transluminal renal
angioplasty |
Anti-hypertensive drug therapy |
12 mo |
Uzzo et al(2002) |
52 |
Randomized controlled clinical trail |
Cleveland
Clinic Foundation |
52 patients with atherosclerotic renovascular disease and hypertension |
surgical |
medical |
74 month |
Wheatley et al
ASTRAL trial
(2007) |
806 |
Randomized
controlled
clinical trial |
57 hospitals (53 in the United
Kingdom, 3 in Australia, and 1 in New Zealand). |
806 patients with atherosclerotic
renovascular disease either to undergo revascularization in addition to receiving
medical therapy or to receive medical therapy alone |
(angioplasty either alone or with stenting with or without medical management |
Medical management (statins, antiplatelet agents, and
optimal blood-pressure control) |
34 months |
Bax et al
STAR trail
(2009) |
140 |
Randomized
controlled
clinical trial |
10 European medical centers. |
Stent placement and medical treatment (64 patients) or medical treatment only (76 patients). |
stent placement and medical treatment |
Medical treatment consisted
of antihypertensive treatment, a statin, and aspirin |
24 month |
Balzer et al
RAOOD
(2009) |
49 |
Randomised
controlled
clinical trial |
University of Düsseldorf |
49 patient with ARVD underwent either Open surgical reconstructive procedure or PTRA± stenting
|
surgery |
Renal artery angioplasty± stenting |
72 month |
